ASPIVIX is pleased to announce a strategic distribution agreement with Titus Health Care to bring Carevix®, our innovative non-traumatic suction cervical stabilizer, to healthcare providers and patients in the Netherlands, Belgium and Luxembourg. This partnership marks another step forward in our mission to modernize gynecology with solutions that put women’s comfort and experience first.
Titus Health Care, based in the Netherlands, is a leading player in women’s health and fertility. Known for its strong clinical network and commitment to innovation, Titus is an ideal partner to expand access to Carevix®—our CE-marked device designed to reduce pain and bleeding during transcervical procedures, such as intrauterine device (IUD) placement.
Fear of pain during IUD insertion remains a major barrier to adoption, affecting 30%to 45% of women globally, an estimated 120 million women each year, primarily due to the use of the traditional cervical tenaculum. In the ADVANCE Women Study, a single-blinded, randomized, multicenter comparative trial, Carevix® demonstrated a 73% reduction in pain and 78% reduction in bleeding during IUD placement compared to the standard tenaculum, becoming a new alternative for better patient experience.
